WIREs Systems Biology and Medicine
Immunity to CRISPR Cas9 and Cas12a Therapeutics

Immunity to CRISPR Cas9 and Cas12a Therapeutics

Genome-editing therapeutics introduce foreign nucleic acids and proteins into the circulation and cells, which can activate the innate, cellular, and humoral immunity in human patients. The key obstacle in translating CRISPR therapeutics to the clinic is hence to identify, diminish, and monitor these immunological risks before adverse immune reactions.